THE REFERENCE FOR FIELD VACCINATION

2

WHEN SHOULD WE APPLY GUMBORO FIELD VACCINATION?

WHY SHOULD I CHOOSE CEVAC ® IBD L?

WHAT SERVICES CAN WE PROVIDE AND WHAT TOOLS ARE AVAILABLE?

3

WHY CEVAC IBD L?FEATURES AND BENEFITS

GUMBORO DISEASECEVAC IBD L : FEATURES AND BENEFITS

CEVA’S WINTERFIELD 2512EARLY AND STRONG PROTECTIONSPREADING ABILITY

GUARANTEED IMMUNOCOMPETENCE

MONITORING AND DIAGNOSIS

IBDV Classification

5

Distance 0.02

849VB/87BEDj/97HU

Nobilis Gumboro D78/INTERVETGumbovax Plus/ISBIBursa Blen/MERIAL

52/70GB

Miss

BG/RIAH

Tad Gumbovac Forte/LOHMANN

KABA/97HU

P3009

Delvax 228TC/Advance Pharma (INTERVET)

UK661/86GB

Soroa/ES

Tri-bio/IN

Bursine Plus/GeneBank

Univax/GeneBank

GLS/87US

Hipragumboro/HIPRA

FS/97HU

Poulvac/SOLVAY

Gumboro/OVEJERO

Izovac Gumboro3/IZO

D78/GeneBank

Izovac Gumboro2/IZOTAD Gumboro/TAD

Gumboral CT/MERIALCu1/76DE

BUR-706/MERIALGallivac IBD/MERIAL

GP82/CEVAPBG98/76GB

P2/73DELIBDV/CEVA

Hipragumboro CH/80/HIPRAGumbovax/IVAZ

228E/GeneBankNobilis Gumboro 228E/INTERVET

VarA/85USVarE/85US

2512/GeneBank2512/CEVA

Bursavac/GeneBankSTC/US

MB/ABICMB71/GeneBankIBD vaccine/VENTRIIV95/INDOVAX

PECS/97HUMOH94/94HU

OKYM/91JPOKYMT/95JP

Bursimune/BIOMUNEPoulvac Bursine2/FORT DODGE

V877/K/GeneBank00273/73Au

Bursavac live/GeneBankBursa Plus/FORT DODGE

MB group

STC group

2512 group

228E group

P2 group

D78 group

Lukert group

V877 group

PHYLOGENETIC TREEIBD VACCINES

(Phylaxia, 2005)

CEVAC ® IBD L

Winterfield 2512 IBD strain.Live freeze-dried -Intermediate Plus type vaccine.Produced on embryonated hen eggs from SPF birds.For the active immunization against classical and very virulent Gumboro disease.By drinking water route at date depending on the level of maternally derived antibodies.

7

FEATURES AND BENEFITS

CEVA’S WINTERFIELD 2512, THE ORIGINAL VACCINE STRAIN

Vaccine strain originated from the first case of IBD (Gumboro, Delaware, USA) in 1960.The methods and number of passages to get the final product are exclusively part of Ceva’s know-how.Classical strain, providing protection against all forms of challenge.

8

Originally, W2512 is a Sanofi Animal Health inc. vaccine strain, the ancestor of CevaDr Winterfield provided his strain to Sanofi AH inc., which has been later on partly sold to Merial select, partly to Ceva; master seeds stocks were split between the two companiesIn the sales agreement, Ceva was obliged to abandon the “Blen” name and to rename all of its vaccines; Merial select got the right to keep Blen name

Important characteristics of isolates of a strain of virus may vary considerably.

FEATURES AND BENEFITS

10

QUICK REPLICATION CAPABILITY

Serology curve in 10-day old SPF birds (study no.1)

0123456789

10111213

0 7 15 21 28

Days of the study

IBD

VN

titr

e (in

log2

)

Competitor 1 Competitor 2 Cevac IBD L Controls

*

*

*: statistical difference

60 SPF chicks with 10 days of age per group were vaccinated with CEVAC® IBD L and 2 competitors through ocular route. Serology was carried out 7, 15, 21 and 28 days after vaccination to evaluate the immune response.

11

QUICK REPLICATION CAPABILITY

Serology curve in 10-day old SPF birds (study no.1)

0123456789

10111213

0 7 15 21 28

Days of the study

IBD

VN

titr

e (in

log2

)

Competitor 1 Competitor 2 Cevac IBD L Controls

*

*

*: statistical difference

60 SPF chicks with 10 days of age per group were vaccinated with CEVAC® IBD L and 2 competitors through ocular route. Serology was carried out 7, 15, 21 and 28 days after vaccination to evaluate the immune response.

CEVAC® IBD L was the first to induce immune response. In other words, CEVAC® IBD L is the fastest to replicate in the bursa, as evidenced by the quickest and highest serological conversion (7 days p-v).

12

QUICK REPLICATION CAPABILTY

IBD Serology curve in 11-day old SPF birds (study no.2)

0

1

2

3

4

5

6

7

8

9

10

11

12

13

0 4 18 32

Days of the study

IBD

VN

tit

re (

in lo

g2)

Competitor 1 Competitor 2 Competitor 3 Competitor 4 Cevac IBD L Controls

*

*

*: statistical difference

IBD vaccination

60 SPF chicks with 11 days of age per group were vaccinated with CEVAC® IBD L and 4 competitors through ocular route. Serology was carried out 7, 15, 21 and 28 days after vaccination to evaluate the immune response.

Evaluation of Evaluation of time needed for the development time needed for the development of protection against vvIBDV infectionof protection against vvIBDV infection,,

after vaccine-takeafter vaccine-take

Objective:

Vaccine-take and protection(vvIBDV)

Phylaxia 2008: Vilmos Palya, Timea Tatar-Kis and Tamas Mato

Scientific Support and Investigation

Materials and Materials and MMethodsethods:: Animals: 3 weeks old SPF chickens (at vaccination) Vaccine:

o Intermediate plus vaccine strain: W 2512 strain1 dose per os

o Intermediate vaccine strain: D78 strain 1 dose per os

Challenge strain:

o vvIBDV strain (D407/2/04TR) from Turkeyo Dose: 105.0 EID50/chickeno Application: per os (200l)

Challenges: o Done at 2 (only W2512), 3, 4 and 5 days (only D78) post-

vaccination Clinical observation done for 13 days post-challenge

Vaccine-take and protection(vvIBDV)

Clinical protection:

• All vaccinated animals were protected against clinical signs or death attributable to challenge (from the first challenge done at 2nd day p.v.-2512 strain or at 3rd day p.v.-D78 strain).

• 20-30% mortality was observed in control challenged groups. All other chicks showed clinical signs of disease (anorexia, trembling, ruffled feathers for 1-3 days). Further 10-40% of animals showed more serious signs: listlessness, severe prostration.

• Each of the control challenged chickens showed severe bursal lesions (histopathology) and low B:B index (0.20-0.25).

Vaccine-take and protection(vvIBDV)

Vaccine-take:

Sampling date

Intermediate plus (W2512)

Intermediate (D78)

Histopathology(positive/total)

Serology (pos/total)

Histopathology(positive/total)

PCR(pos/total)

Serology (pos/total)

2nd day p.v. 5/5 1/5 NT

3rd day p.v. 5/5 3/5 4/5 4/5 0/5

4th day p.v. 5/5 4/5 3/5 4/5 0/5

5th day p.v. NT 4/5 5/5 1/5

NT: not tested

Vaccine-take and protection(vvIBDV)

Protection against challenge with vvIBDV:

Intermediate plus vaccine (W 2512 strain) CEVAC IBD L

Challenge date

At challenge 4 days p.ch.

Histopathology (positive/tested)

Serology (pos./tested)

Histopathology(protected/tested)

RFLP(Vaccine/ vvIBDV)

2 days p.v. 5/5 1/5 5/5 5/0

3 days p.v. 5/5 3/5 5/5 3/0*

4 days p.v. 5/5 4/5 5/5 5/0*Only 3 out of 5 PCR positive samples were tested by RFLP.

Vaccine-take and protection(vvIBDV)

Protection against challenge with vvIBDV:

Intermediate vaccine (D78 strain)

Challenge date

At challenge 4 days p.ch.

Histop. PCR Serology

Histopathology RFLP

No protection

Partial protection Only

D78Only

vvIBDV<50%* ≥50%*

3 days p.v. 4/5 4/5 0/5 4/5 1/5 - - 5/5

4 days p.v. 3/5 4/5 0/5 4/5 - 1/5 1/5(rev. D78)

4/5

5 days p.v. 4/5 5/5 1/5 3/5 1/5 1/5 - 5/5

* Percentage of protected follicules

Vaccine-take and protection(vvIBDV)

Conclusions:Conclusions: Both vaccines protected all animals from death/clinical signs as early

as 2 or 3 days post-vaccination.

Vaccine-take was observed • 2 days post-vaccination, and was complete (in 100% of chickens)

by 3 dpv in case of intermediate plus strain (2512)• 3 days post-vaccination, and was not complete until 5 dpv in case

of intermediate strain (D78)

The intermediate plus vaccine inhibited the replication of the challenge virus in the bursa right after vaccine-take PROTECTION AGAINST INFECTION!!

The intermediate vaccine could not protect or only partially protected the bursa from histopathological lesions caused by the challenge virus

VACCINE-TAKE AND PROTECTION (VVIBDV)

20

THE BEST SOLUTION FOR DRINKING WATER VACCINATION

• Spreading ability• Enhancing the vaccination coverage• Homogenous protection

WHY CEVAC IBD L?FEATURES AND BENEFITS

21

SPREADING ABILITY

0

1

2

3

4

10 15 20 25 30 35 40 45 50 55

Age (days)

VN

(lo

g10)

Vaccinated

Contacts unvaccinated

Control

Cevac IBD L

Contacts Unvaccinated birds (birds not vaccinated but kept in contact with vaccinated ones) had the same level of seroconversion than vaccinated birds.CEVAC® IBD L spreads from vaccinated to unvaccinated birds, providing full protection.

22

Any IBD live vaccine MUST colonize and replicate in the bursa to provide protection.

Changes are normal and reversibleDon’t compromise immunocompetenceDon’t correlate with performance

Billions of vaccinated birds wwUsed by all major producing countries.Tested according Ph.EurOutstanding income results and performance recorded

GUARANTEED IMMUNOCOMPETENCE

Greece, 1998: Comparative trial on productive performance using Cevac IBD L•Group 1 : 20,000 vaccinated at 14 days of age with CEVAC IBD L•Group 2 : 30,000 vaccinated at 14 days of age with an intermediate plus competitor•Slaughter age at 48 days for group 1 and at 47 days for group 2

Cevac IBD L group obtained better productive performance than the

competitor in the field.

Comparative Field Trials

Poland, 1998: Mortality and serological response using Cevac IBD L.5 broiler farms, 250,000 birds, on 2 to 4 cycles per farm. One single administration of either CEVAC IBD L or competitor intermediate plus vaccine at 14-17 days of age Slaughter age in Farm 3 and 5: 45 days.

Cevac IBD L groups obtained lower mortality rates

and outstanding levels of ELISA titers at slaughter.

Comparative Field Trials

China, 1994: Profit using a single dose of Cevac IBD L.•Arbor Acres Broilers.•70,000 broilers in 3 houses vaccinated with CEVAC IBD L at 18 days •90,000 in 4 houses vaccinated with a Gumboro vaccine produced by a local company at 18 and 30 days. •Slaughter age at 57 – 58 days

Percentages of profit were significantly

better when Cevac IBD L was used.

Comparative Field Trials

Malaysia, 1994: Performance index using Cevac IBD L versus competitor.  13,000 Arbor Acres broiler chickens Group 1 : 6,500 birds vaccinated with CEVAC IBD L at 12 days of age Group 2 : 6,500 birds vaccinated with a intermediate plus competitor vaccine at 12 days of age Slaughter at 45 days of age

Performance index was better in flocks

vaccinated with Cevac ® IBD L.

Comparative Field Trials

Thailand, 1998: Weight gain with Cevac IBD L in vvIBD experimental challenge. 208 broilers vaccinated at D14 with Cevac IBD L and 3 other intermediate plus vaccinesBirds challenged with vvIBD strain at D28

J.Sasepreeyajan et al: Relative virulence and efficacy of intermediate plus IBD vaccines in broilers-1998. Division of Avian Medicine. Bangkok, Thailand. Unpublished experimental report

Cevac ® IBD L vaccinated animals have the highest rates of gain weight after vvIBD experimental challenge.

Comparative Field Trials

Philippines, 1998: Comparative trial on Bursal lesion scores after use of Cevac IBD L versus competitors. •Comparative trial using 3 intermediate plus vaccines•Age at vaccination 16 days•Bursal scores at 10 days after vaccination.

The mean value of bursal lesion scores in vaccinated chickens was lower for Cevac IBD L group than for the others intermediate plus vaccines, meaning better safety.

Comparative Field Trials

Mortality rates were lower for the flocks vaccinated

with Cevac IBD L.

Morocco, 2000: Mortality rates in 4 flocks vaccinated with CEVAC IBD L versus other intermediate plus vaccines.•Group 1 : 4 flocks vaccinated with CEVAC IBD L• Group 2 : 2 flocks vaccinated with another Intermediate Plus vaccine

Comparative Field Trials

Thank youThank you